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Pharmacodynamic modelling of in vitro 
activity of tetracycline against a representative, 
naturally occurring population of porcine 
Escherichia coli
Amais Ahmad1*†, Camilla Zachariasen2†, Lasse Engbo Christiansen3, Kaare Græsbøll3, Nils Toft4, 
Louise Matthews5, Peter Damborg2, Yvonne Agersø6, John Elmerdahl Olsen2 and Søren Saxmose Nielsen1
Abstract 
Background: The complex relationship between drug concentrations and bacterial growth rates require not only 
the minimum inhibitory concentration but also other parameters to capture the dynamic nature of the relationship. 
To analyse this relationship between tetracycline concentration and growth of Escherichia coli representative of those 
found in the Danish pig population, we compared the growth of 50 randomly selected strains. The observed net 
growth rates were used to describe the in vitro pharmacodynamic relationship between drug concentration and net 
growth rate based on Emax model with three parameters: maximum net growth rate (αmax); concentration for a half-
maximal response (Emax); and the Hill coefficient (γ).
Results: The net growth rate in the absence of antibiotic did not differ between susceptible and resistant isolates 
(P = 0.97). The net growth rate decreased with increasing tetracycline concentrations, and this decline was greater in 
susceptible strains than resistant strains. The lag phase, defined as the time needed for the strain to reach an OD600 
value of 0.01, increased exponentially with increasing tetracycline concentration. The pharmacodynamic parameters 
confirmed that the αmax between susceptible and resistant strains in the absence of a drug was not different. EC50 
increased linearly with MIC on a log–log scale, and γ was different between susceptible and resistant strains.
Conclusions: The in vitro model parameters described the inhibition effect of tetracycline on E. coli when strains 
were exposed to a wide range of tetracycline concentrations. These parameters, along with in vivo pharmacokinetic 
data, may be useful in mathematical models to predict in vivo competitive growth of many different strains and for 
development of optimal dosing regimens for preventing selection of resistance.
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Background
Resistance to antimicrobials is a continuous challenge 
to the public health care system [1]. In vitro growth 
response of bacterial strains to antimicrobial is required 
to evaluate carefully before designing treatment proto-
cols for antimicrobial use. Tetracycline is a widely used 
broad-spectrum antimicrobial that inhibits the growth of 
many bacteria. It is the most commonly used drug against 
gastrointestinal infectious diseases in pig production in 
Denmark, a production system that accounted for 76 % of 
the total veterinary consumption in kg active compound 
in 2012 [2]. It is also used in humans, with 11  % of the 
total consumption of antimicrobials being used in pri-
mary health care in Denmark in 2012 [2]. Tetracyclines 
exert concentration and time-dependent antimicrobial 
effects [3]. After binding to the ribosome, tetracyclines 
inhibit the binding of aminoacyl-tRNA to the messenger 
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RNA molecule/ribosome complex, thereby interfering 
with bacterial protein synthesis in growing or multiply-
ing organisms [4]. Tetracycline resistance is generally due 
to the acquisition of genes [5, 6], encoding either energy 
dependent efflux proteins, which transfer tetracyclines 
out of the bacterial cell, ribosomal protection proteins, 
which make the ribosome insensitive to tetracycline inhi-
bition by interacting with the tetracycline binding site(s), 
or enzymes, which deactivate tetracyclines in the pres-
ence of oxygen [7].
Escherichia coli is commonly used as an indicator bac-
terium for antimicrobial resistance in animals, humans, 
and food products [2]. In Denmark, 36 % of commensal 
E. coli obtained from pigs were resistant to tetracycline, 
and efflux pumps TetA and TetB were found to encode 
for resistance in a subset of E. coli isolates from 2012 
[2, 8]. Such a high level of resistance is worrisome con-
sidering the widespread use of tetracyclines against dis-
eases (e.g. post-weaning diarrhoea) where E. coli is often 
involved. Furthermore, resistance may spread horizon-
tally to other bacterial species in the gut microbiota. 
Understanding the relation between tetracycline expo-
sure and the growth response of porcine E. coli strains is 
important to aid in improving dosing strategies and pos-
sibly reduce the resistance problem.
Growth response of bacterial strains exposed to a 
specific antimicrobial agent is usually evaluated based 
on pharmacodynamics (PD) of antimicrobials. In such 
studies, strains are commonly characterized by the PD 
parameter minimum inhibitory concentration (MIC), 
defined as the lowest antibiotic concentration that pre-
vents visible growth of the bacterial population in vitro 
[9–11]. This parameter is measured only at one time 
point after exposure of the bacterial population to a con-
stant antimicrobial concentration, and it does not reflect 
the time-inhibition process. A more useful approach is 
to base in vitro models on time kill curves [12, 13] using 
a modelling approach where the relationship between 
estimated growth rates and antimicrobial concentrations 
is analysed by maximum-effect (Emax) models. Such 
Emax-models are based on three key PD parameters: 
maximum growth rate, i.e., growth without antimicro-
bial pressure, drug concentration leading to a half-max-
imum effect (EC50); and the Hill’s coefficient, describing 
the steepness of a sigmoid Hill equation [9, 10]. These 
parameters along with in  vivo pharmacokinetics (PK) 
have been used as an input for the mathematical models 
of in vivo bacterial growth [14–18]. These in vivo models 
have been used to propose new treatment strategies [19, 
20]. Inference based on the in  vivo model predictions 
can be used to design treatment strategies to, helping 
reduce costly clinical studies and the use of experimental 
animals [19, 21].
The aim of the current study was first to investigate the 
relation between tetracycline concentration and growth 
performance of a representative collection of commen-
sal intestinal strains of E. coli and second to estimate PD 
parameters and their association with MIC values in the 
presence of increasing concentrations of antibiotics using 
an in vitro PD model.
Methods
Strain selection
In 2010, 160 porcine commensal E. coli isolates were 
obtained from the same number of healthy pigs from dif-
ferent herds at slaughter as part of the Danish Integrated 
Antimicrobial Resistance Monitoring and Research Pro-
gram (DANMAP) [22]. Among these isolates, 50 were 
selected randomly for this study. The selection was per-
formed using a computerized random sample generator, 
and it was considered to be representative of the Dan-
ish pig population. Isolates were confirmed as E. coli by 
matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometry [23] using E. coli 
ATCC 8739 as reference strain and SaramisTM 3.5 (bio-
Mérieux) for spectra interpretation.
Susceptibility to tetracycline
The susceptibility to tetracycline was tested in two-fold 
dilutions between 0.125 and 512  µg/ml tetracycline 
hydrochloride (Sigma-Aldrich, Switzerland) for all 50 iso-
lates using broth microdilution following the Clinical and 
Laboratory Standards Institute (CLSI) standards [24]. 
Briefly, two-fold dilutions of tetracycline were prepared 
in Cation-Adjusted Mueller-Hinton 2 broth (MH-2) 
(Sigma-Aldrich, Switzerland) and distributed on micro-
titre plates. Bacterial saline suspensions were prepared 
from overnight cultures on blood agar and adjusted to a 
0.5 McFarland turbidity standard. The suspensions were 
diluted 1:100 in MH-2 and this suspension was used as 
inoculum of the wells, giving a final concentration of 
approximately 5 × 105 CFU/ml. E. coli ATCC®25922 was 
used as a quality control. Isolates with MIC ≥16  µg/ml 
tetracycline were considered to be tetracycline resistant 
[25].
Growth curves
Growth curves for the effect of tetracycline on the 50 E. 
coli strains were obtained using the automated microbi-
ology growth curve analysis system BioScreen CTM (Oy 
Growth Curves Ab Ltd, Finland). Two-fold dilutions of 
tetracycline hydrochloride were distributed into Bio-
Screen plates. Bacterial saline suspensions were prepared 
from overnight cultures on blood agar and adjusted to 
a 0.5 McFarland turbidity standard. These suspensions 
were diluted 1:100 in MH-2, and inoculated to the plates 
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to give a final concentration of approximately 5 × 104 
CFU/ml. Final volume in each well was 200  µl. Suscep-
tible isolates were grown in two-fold dilutions of tetracy-
cline ranging from 0.03 to 8 µg/ml, and resistant isolates 
were grown in two-fold dilutions ranging from 0.5 to 
128  µg/ml of tetracycline. All isolates were additionally 
grown in MH-2 without antibiotics. The BioScreen was 
set to 18  h incubation at 37  °C with continuous shak-
ing and optical density (OD) at 600 nm measured every 
5  min. All experiments were performed in biological 
triplicates, meaning that bacterial culture, adjustment of 
cell density, preparation of tetracycline suspensions, and 
running on the BioScreen were done three times for each 
tested strain. Strains that do not grow because of MIC 
above the concentration tested were assigned a growth 
rate of zero.
Analysis of growth curves
The BioScreen raw data were extracted in Microsoft 
Excel. OD values of blank samples were subtracted from 
sample OD values at the respective time points before 
analysing the data.
The effect of tetracycline on growth of E. coli was 
assessed from the net growth rate (µ) of the strains at 
various tetracycline concentrations. The linear relation-
ship between CFU and OD is only valid for low cell con-
centrations, and this relation becomes unreliable above 
a certain critical value [26, 27]. An OD of 0.1 was taken 
as a maximum reliable value in this study. Exponential 
growth part of growth curves below this cut-off was used 
for the model fit. The following model equation was used:
where Yt is the OD value, λ is the initial OD value at time 
zero, µ is the growth rate, β is an offset variable for the 
adjustment of λ, and εt normal error with mean zero and 
constant variance σ 2; i.e., εt = N (0, σ 2). Growth rates for 
the 50 E. coli strains at each concentration level were esti-
mated by fitting the model (Eq. 1) to growth curves using 
a nonlinear least square algorithm nls() function of the R 
statistical software [28].
The lag phase could not be identified from the OD 
results using the BioScreen. To get an indication of the 
effect of tetracycline on growth onset of E. coli, the time 
needed for the different strains to reach an OD value of 
0.01 at the various tetracycline concentrations was ana-
lysed. Growth onset values were determined as the first 
time value at which OD was equal to or slightly greater 
than 0.01. Because the growth onset between triplicates 
can be influenced by external factors, growth onset 
relative to growth onset when grown without tetracy-
cline was calculated for each triplicate and tetracycline 
concentration.
(1)Yt = eµt + β + εt
A Kruskal–Wallis one-way analysis of variance and 
Wilcoxon rank-sum test was used to compare the growth 
rates and relative growth onset between tetracycline sus-
ceptible and resistant strains at various tetracycline con-
centrations using R [28]. The level of significance was set 
at P < 0.05.
Pharmacodynamic model
The relationship between the tetracycline concentration 
and the estimated net bacterial growth rates was analysed 
using the sigmoid Emax model [17, 29–31]. The net E. coli 
growth rate as a function of drug concentration c was 
described previously [17]:
where αmax is the bacterial growth rate in the absence of 
the drug (maximum effect), EC50 is the concentration at 
which the drug effect is reduced to 50 %, and γ denotes 
the Hill coefficient, which is the measure of the steepness 
of the sigmoid relationship between concentration c and 
the growth rate at concentration c. Growth rates in tripli-
cates derived from the exponential growth model (Eq. 1) 
were plotted against the concentration range and fitted to 
the model given by Eq. 2 for each of the 50 E. coli strains, 
using a nonlinear least square algorithm nls() function of 
R [28]. PD model parameters αmax and γ were compared 
for susceptible and resistant strains using the Wilcoxon 
rank-sum test in R, whereas the linear relation between 
MIC and EC50 was analysed using the lm() function in R.
Results
Tetracycline MIC distributions
All isolates were verified as E. coli by MALDI-TOF MS 
analysis. Antibiotic resistance patterns of the 50 ran-
domly selected isolates had previously been determined 
as part of the Danish Integrated Antimicrobial Resistance 
Monitoring and Research Programme 2010, however, 
only for tetracycline concentrations between 2 and 32 µg/
ml [22], and therefore susceptibility towards this drug 
was examined in more detail in the current study. Among 
the 50 isolates, seventeen (34 %) were resistant to tetracy-
cline with an MIC ≥16 µg/ml.
Growth response to different concentrations of tetracycline
Growth curves of a single E. coli in triplicate at different 
concentrations of tetracycline are shown in Fig.  1, with 
an exponential model fit indicated by the solid lines. The 
drug showed a clear inhibition effect with increasing con-
centrations, whereas growth onset was shown to increase 
with increasing concentrations of the antibiotic.
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In the absence of tetracycline, only minor insignificant 
variations between the net growth rates of the individual 
E. coli strains were found, indicating a lack of fitness cost, 
and no significant correlation was found between the 
MIC-values and growth rates (Fig.  2a). When analysed 
as groups, the net growth rates of tetracycline suscepti-
ble and resistant isolates did not differ in the absence of 
antibiotics, however at tetracycline concentrations corre-
sponding to 1/2, 1/4, 1/8 of the MIC value of the strains, the 
growth rates were significantly less affected in the resist-
ant isolates than the susceptible ones (Fig.  2b). Overall, 
the effect of sub-MIC concentrations of tetracycline on 
onset of growth (time to reach OD  =  0.01) increased 
exponentially with increasing tetracycline concentration 
(Fig.  2c). When expressed within sub-MIC group, the 
effect of the concentration of drug on onset of growth 
was not statistically significant at any of the tetracycline 
concentrations between tetracycline susceptible and 
resistant strains (data not shown).
Pharmacodynamic modelling
The MIC distribution of strains is presented in Fig.  3a. 
Model parameter αmax did not differ significantly 
(P  =  0.97) between resistant and susceptible strains 
(Fig.  3b). In contrast, the Hill coefficients (γ), capturing 
the steepness of response to tetracycline, were smaller 
for susceptible strains than resistant strains (P < 0.00001; 
Fig.  3c), showing that the susceptible strains were more 
affected by low concentrations of drugs than resistant 
ones. There was a significant linear relationship between 
MICs and EC50 values on the log–log scale (P < 0.00001; 
Fig. 3d) with an R2 of 0.99.
Discussion
This is to our knowledge the first large-scale study inves-
tigating the effect of tetracycline on growth in E. coli 
obtained randomly from healthy pigs in different farms. 
The study was based on in  vitro growth curves, which 
were used to fit an in vitro PD model for the inhibitory 
effect of tetracycline. This approach greatly increases the 
possibility of including many strains and many concen-
trations of antibiotics. In contrast, previous studies that 
have characterized the growth effect of antimicrobials on 
E. coli were based on manual growth curves for a limited 
number of strains, most often of clinical origin [32–35]. 
Clinical E. coli are more likely to be resistant than com-
mensal strains [2], thus our decision to include a large 
number of commensal strains illustrates better the full 
diversity of MIC-distributions present in E. coli at herd 
level.
We focused on the differences in activity of tetracy-
cline against tetracycline susceptible and resistant E. coli 
using real time growth curves. Growth curves were fitted, 
and in vitro PD parameters were derived using the Emax 
model by fitting the relation between concentration and 
net bacterial growth rates.
Fig. 1 Growth curves of a strain with MIC = 0.5 µg/ml under range of tetracycline concentrations with maximum OD value of 0.1. Each colour 
represents growth in triplicates at a specific concentration
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We did not find any association between growth rates 
and MIC values in the absence of tetracycline, i.e. the 
maximum net growth rate αmax (growth in the absence 
of drug) was found to have no significant difference 
between susceptible and resistant strains. The lack of fit-
ness costs associated with tetracycline resistance might 
be explained by the mechanism by which tetracycline 
resistance genes are regulated.
Basing the study on growth performance in BioScreen 
had some limitations. A true relation between colony 
forming units and OD values was unknown, and a lin-
ear relation was assumed with a maximum OD value of 
0.1. Growth onset was defined as the time needed for 
the cells to reach the exponential growth phase follow-
ing the lag phase. We defined growth onset as the time 
for a strain to reach an OD value of 0.01, as preliminary 
experiments showed this OD value to be part of the early 
exponential phase (data not shown). Future experiments 
with manually obtained growth curves in flasks could 
overcome these limitations, but the advantage of being 
able to include many strains in the study was considered 
the critical goal.
EC50 was highly correlated with the MIC, showing a 
strong relationship between this point estimate param-
eter and the dynamic activity of tetracycline, i.e. the anti-
microbial concentration required to produce 50 % of the 
maximum effect EC50 was found to increase linearly with 
MIC values on a log–log scale. A likely explanation is that 
MIC reflects a difference between strains in the ability to 
pump out tetracycline and that this inherent difference 
between strains is not dependent on concentration of 
tetracycline. In that situation, a strain that is superior at 
one concentration of drug will also be superior at another 
concentration. It should be noted that EC50 values occa-
sionally differed among strains with similar MIC values, 
but this may be explained by methodological shortcom-
ings. For example, the inoculum density in the BioScreen 
setup was slightly lower than the density used for MIC 
testing. Furthermore, MIC values are associated with 
uncertainty (two fold) and some degree of subjectivity, 
Fig. 2 a Net growth rate (h−1) of the isolates in the absence of tetracycline, grouped according to tetracycline MIC. b Net growth rate (h−1) of tetra-
cycline susceptible and resistant isolates grown in increasing concentrations of tetracycline. c Relative growth onset of the isolates when grown in 
increasing concentrations of tetracycline. a, b Green box plots refer to estimated net growth rates of tetracycline susceptible isolates, red boxplots to 
estimated net growth rates from tetracycline resistant isolates. Black dots indicate mean net growth rate (h−1) of the individual isolates. a–c Outliers 
are shown as circled dots. The number of isolates in each group is indicated in brackets
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whereas the OD-based values here are recorded objec-
tively using BioScreen CTM. Also, in the BioScreen exper-
iments the strains were grown with constant shaking, 
as opposed to the MIC assay without shaking. Constant 
shaking makes E. coli grow faster due to the aeration of 
the culture supplying the bacteria with plenty of oxygen. 
There is also variation associated with the EC50 estimates, 
but to a lower degree, as it is (generally) well-defined 
within two tested concentrations.
The steepness of response to tetracycline concentrations 
was found to be greater in the case of resistant strains, but 
estimates were associated with large uncertainty. Thus, 
this result should be viewed with more caution than 
other, since relatively high values of γ in resistant strains 
could be due to the fewer data points around the EC50. 
Additional in  vitro growth experiments were performed 
including tetracycline concentrations between some of 
the higher two-fold dilutions, in order to overcome this 
problem (data not shown). Still, it was not possible, within 
the limitations of the study, to obtain as many data points 
for the high MIC values as for the low ones.
Conclusions
This study based on in  vitro growth experiments of the 
complex relationship between E. coli growth and tetracy-
cline concentration showed that along with MIC values, 
there are other parameters that govern this relationship. 
These parameters should also be taken into account in 
addition to the MIC when studying the bacterial response 
to antimicrobials and were described and estimated in 
this study using pharmacodynamic modelling. These 
parameters better capture the dynamic activity of a drug, 
for which point estimate MIC cannot account, and this 
may affect the in  vivo outcomes. The estimated in  vitro 
PD population based parameters may be used along 
with in  vivo pharmacokinetics in mathematical mod-
els for predicting the in vivo growth of multiple strains. 
Predictions from these in  vivo models may be useful in 
optimizing dosing regimens for suppressing selection of 
resistance. Although this study did not identify fitness 
costs, further work to characterize the potential impact 
of fitness costs in a population based setting is needed, 
since the presence of fitness costs is a commonly-made 
Fig. 3 a Distribution of 50 E. coli strains according to MIC values. b–d Three PD parameters from Emax model of 50 E. coli strains according to their 
MIC values with mean and 95 % confidence interval. The green line represents susceptible isolates and the red line represents resistant isolates. A 
vertical black line is drawn at cut-off between susceptible and resistant isolates
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assumption in research on antimicrobial resistance, in 
particular in relation to the disappearance of resistant 
bacteria in the absence of antimicrobial drug.
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